NCT06998940View on ClinicalTrials.gov

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

January 6, 2026

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Adenocarcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Fluorouracil

Given IV

DRUG

Gemcitabine

Given IV

DRUG

Irinotecan

Given IV

DRUG

Irinotecan Sucrosofate

Given IV

DRUG

Leucovorin

Given IV

DRUG

Nab-paclitaxel

Given IV

BIOLOGICAL

Panitumumab

Given IV

OTHER

Questionnaire Administration

Ancillary studies

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

SWOG Cancer Research Network

NETWORK